Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Takuji Okusaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1729-807X; OpenAlex author ID A5022558782, A5030913868, A5076696174. Sources: ClinicalTrials.gov.

Their work

Papers
92 (first author 15, last author 18)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
274
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: 5 papers · 2012: 8 papers · 2013: 2 papers · 2014: 5 papers · 2015: 10 papers · 2016: 8 papers · 2017: 9 papers · 2018: 5 papers · 2019: 3 papers · 2020: 5 papers · 2021: 4 papers · 2022: 6 papers · 2023: 10 papers · 2024: 4 papers · 2025: 5 papers · 2026: 3 papers

Papers 50 of 92

  1. Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic… Co-author DOI 10.1002/jhbp.70106↗
  2. Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study. Co-author DOI 10.1111/cas.70344↗
  3. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  4. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  5. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design. First author DOI 10.1080/14796694.2025.2469467↗
  6. Prospective, multicentre trial on preoperative biliary drainage by endoscopic ultrasound-guided hepaticogastrostomy for resectable/borderline resectable pancre… Last author DOI 10.1136/bmjopen-2025-106543↗
  7. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  8. Third-line S-1 or FOLFOX treatment in advanced pancreatic cancer who received gemcitabine+nab-paclitaxel and nanoliposomal-irinotecan+5-fluorouracil/leucovorin Last author DOI 10.21203/rs.3.rs-5801148/v1↗
  9. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy. Last author DOI 10.1002/cam4.70474↗
  10. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. Co-author DOI 10.1038/s44276-023-00028-4↗
  11. Safety of biliary drainage with 6-mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY. Last author DOI 10.1111/jgh.16524↗
  12. Study Protocol for a Prospective Self-Controlled Trial on Success in Meeting Comprehensive Genomic Profiling Analysis Criteria for Specimens Obtained by Endosc… Last author DOI 10.3390/diseases12080182↗
  13. Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. Co-author DOI 10.1007/s00535-022-01944-x↗
  14. Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort. Co-author DOI 10.1007/s00535-023-02033-3↗
  15. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  16. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… First author DOI 10.1016/j.eclinm.2023.101897↗
  17. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  18. Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan. Last author DOI 10.1016/j.pan.2023.10.017↗
  19. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety… Co-author DOI 10.1093/jjco/hyac177↗
  20. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  21. Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancr… Last author DOI 10.1111/den.14423↗
  22. Clinical course of anorexia-cachexia according to type of first-line chemotherapy for advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3048794/v1↗
  23. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. Co-author DOI 10.1007/s00535-022-01920-5↗
  24. Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System … Last author DOI 10.1007/s00535-022-01926-z↗
  25. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. Last author DOI 10.1007/s10147-022-02186-w↗
  26. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Last author DOI 10.1016/j.ejca.2022.06.010↗
  27. Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreat… Last author DOI 10.1016/j.pan.2022.04.006↗
  28. Treatment for postoperative recurrence of pancreatic cancer: a narrative review. Co-author DOI 10.21037/cco-21-87↗
  29. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Last author DOI 10.1007/s10147-021-02001-y↗
  30. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  31. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  32. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  33. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
  34. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. Co-author DOI 10.1007/s00535-020-01666-y↗
  35. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Co-author DOI 10.1007/s10147-020-01721-x↗
  36. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  37. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000001513↗
  38. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Co-author DOI 10.1007/s10637-018-0634-5↗
  39. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  40. Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Co-author DOI 10.2169/internalmedicine.2539-18↗
  41. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-018-3577-9↗
  42. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Last author DOI 10.1007/s00535-018-1466-y↗
  43. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic … Co-author DOI 10.1016/j.pan.2018.07.007↗
  44. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  45. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Co-author DOI 10.1097/mpa.0000000000001052↗
  46. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gem… Co-author DOI 10.1007/s00280-017-3351-4↗
  47. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. First author DOI 10.1007/s00432-017-2349-y↗
  48. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Co-author DOI 10.1016/j.cca.2017.02.011↗
  49. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. First author DOI 10.1038/bjc.2017.128↗
  50. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Co-author DOI 10.1093/jjco/hyx075↗

Trials 1

  1. Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer Principal investigator NCT00498225↗

Closest collaborators

The 25 strongest of 274 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junji Furuse · 38 shared papers, 2011–2026 · strength 3.42
  2. Chigusa Morizane · 32 shared papers, 2011–2025 · strength 3.39
  3. Masafumi Ikeda · 36 shared papers, 2011–2026 · strength 3.35
  4. Makoto Ueno · 21 shared papers, 2012–2026 · strength 2.60
  5. Tatsuya Ioka · 29 shared papers, 2011–2026 · strength 2.10
  6. Susumu Hijioka · 10 shared papers, 2022–2026 · strength 1.83
  7. Masato Ozaka · 12 shared papers, 2014–2026 · strength 1.60
  8. Akihiro Ohba · 10 shared papers, 2021–2025 · strength 1.55
  9. Hiroshi Ishii · 16 shared papers, 2013–2026 · strength 1.24
  10. Hideki Ueno · 15 shared papers, 2011–2024 · strength 1.17
  11. Nobuyoshi Hiraoka · 9 shared papers, 2014–2026 · strength 1.03
  12. Nobumasa Mizuno · 13 shared papers, 2014–2023 · strength 1.01
  13. Tomoyuki Satake · 5 shared papers, 2022–2024 · strength 0.95
  14. Daiki Yamashige · 5 shared papers, 2023–2026 · strength 0.94
  15. Hideki Ueno · 16 shared papers, 2012–2021 · strength 0.93
  16. Satoshi Kobayashi · 7 shared papers, 2016–2026 · strength 0.90
  17. Shota Harai · 5 shared papers, 2022–2026 · strength 0.89
  18. Naoki Sasahira · 6 shared papers, 2019–2026 · strength 0.81
  19. Shoji Nakamori · 15 shared papers, 2011–2021 · strength 0.80
  20. Naohiro Okano · 6 shared papers, 2020–2025 · strength 0.76
  21. Go Ikeda · 4 shared papers, 2022–2026 · strength 0.70
  22. Shuichi Mitsunaga · 10 shared papers, 2011–2023 · strength 0.67
  23. Akira Fukutomi · 11 shared papers, 2013–2021 · strength 0.66
  24. Kazuaki Shimada · 10 shared papers, 2012–2023 · strength 0.65
  25. Kotaro Takeshita · 4 shared papers, 2022–2025 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.